Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia

Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting

(2016) Angie M. Y. Shum et al.   Aging-US

A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer

(2015) Ya-Ting Yang et al.   NEOPLASIA

HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy

(2014) A. W. Beharry et al.   JOURNAL OF CELL SCIENCE

Biochemistry and pathophysiology of intravascular and intracellular lipolysis

(2013) S. G. Young et al.   GENES & DEVELOPMENT

The role of triglyceride lipases in cancer associated cachexia

(2013) Suman K. Das et al.   TRENDS IN MOLECULAR MEDICINE

Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia

(2013) Hirak Der-Torossian et al.   Journal of Cachexia Sarcopenia and Muscle

Abstract 5101: Biomarker identification in non-small cell lung cancer (NSCLC) with activity-based proteomics

(2012) Thomas Wiedl et al.   CANCER RESEARCH

Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways

(2012) Kenneth C.H. Fearon et al.   Cell Metabolism

Cellular and molecular mechanisms of muscle atrophy

(2012) P. Bonaldo et al.   Disease Models & Mechanisms

Current pharmacotherapy options for cancer anorexia and cachexia

(2012) Antonio Macciò et al.   EXPERT OPINION ON PHARMACOTHERAPY

Acetylation and deacetylation—novel factors in muscle wasting

(2012) Nima Alamdari et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle

(2011) Sarah M. Senf et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy

(2011) Sarah A. Reed et al.   FASEB JOURNAL

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

The role of insulin resistance in the development of muscle wasting during cancer cachexia

(2011) Mary A. Honors et al.   Journal of Cachexia Sarcopenia and Muscle

Treating cancer cachexia to treat cancer

(2011) Se-Jin Lee et al.   Skeletal Muscle

Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites

(2010) Roman Eisner et al.   Metabolomics

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

(2010) David M. Lucas et al.   PLoS One

α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population

(2010) Walter E. Gall et al.   PLoS One

Cachexia as a major underestimated and unmet medical need: facts and numbers

(2010) Stephan von Haehling et al.   Journal of Cachexia Sarcopenia and Muscle

Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice

(2009) A. Bonetto et al.   CURRENT CANCER DRUG TARGETS

Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice

(2009) Michelle L. Asp et al.   INTERNATIONAL JOURNAL OF CANCER

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of Cancer Cachexia

(2009) Michael J. Tisdale   PHYSIOLOGICAL REVIEWS

OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model

(2008) A. M. Sargeant et al.   CANCER RESEARCH